Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017

Comparison of ceftazidime-avibactam and ceftolozane-tazobactam in vitro activities when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2017–2018)

Published:2020-03 Issue:3 Volume:96 Page:114833
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Sader Helio S.,Flamm Robert K.,Carvalhaes Cecilia G.,Castanheira Mariana

Funder

Allergan

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference24 articles.

1. AVYCAZ®. AVYCAZ® (ceftazidime-avibactam). 2018. https://www.allergan.com/assets/pdf/avycaz_pi. Accessed Allergan USA, Inc.February 2018.

2. Pseudomonas aeruginosa: all roads lead to resistance;Breidenstein;Trends Microbiol,2011

3. Antimicrobial activity of ceftolozane-tazobactam tested against gram-negative contemporary (2015-2017) isolates from hospitalized patients with pneumonia in US medical centers;Carvalhaes;Diagn Microbiol Infect Dis,2019

4. Changes in the frequencies of beta-lactamase genes among Enterobacteriaceae isolates in U.S. hospitals, 2012 to 2014: activity of ceftazidime-avibactam tested against beta-lactamase-producing isolates;Castanheira;Antimicrob Agents Chemother,2016

5. Clinical and Laboratory Standards Institute. M100Ed28E. Performance standards for antimicrobial susceptibility testing: 28th informational supplement. Wayne, PA: CLSI,2018

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Friends or foes? Novel antimicrobials tackling MDR/XDR Gram-negative bacteria: a systematic review;Frontiers in Microbiology;2024-05-10

2. Activity of ceftolozane/tazobactam, imipenem/relebactam and ceftazidime/avibactam against clinical Gram-negative isolates—SMART United States 2019–21;JAC-Antimicrobial Resistance;2023-12-28

3. In vitro synergy of the combination of sulbactam-durlobactam and cefepime at clinically relevant concentrations against A. baumannii, P. aeruginosa and Enterobacterales;Journal of Antimicrobial Chemotherapy;2023-10-16

4. Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections;Clinical Infectious Diseases;2023-07-18

5. Infection control measures against multidrug-resistant Gram-negative bacteria in children and neonates;Future Microbiology;2023-07